Compositions and Methods for Reprogramming Diseased Musculoskeletal Cells

USPTO published patent application US20260097131A1 disclosing compositions and methods for reprogramming diseased musculoskeletal cells both in vitro and in vivo. The method involves non-virally delivering intracellularly into diseased musculoskeletal cells a polynucleotide comprising one or more nucleic acid sequences encoding disclosed transcription factors. CPC classifications include A61K 48/0025, A61P 21/00, C07K 14/4702, C12N 15/85, and C12N 2800/107.

For biotechnology companies, pharmaceutical firms, and research institutions developing cell-based therapies for musculoskeletal diseases, this patent application represents potential prior art that could affect freedom-to-operate analyses. Parties engaged in similar reprogramming technologies should monitor this application's prosecution status and consider filing protests or observations during examination.